Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR 176.70
+4.71 (2.74%)
Jul 10, 2026, 3:30 PM IST
Piramal Pharma Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Piramal Pharma stock has a consensus rating of "Strong Buy" and an average price target of ₹203.00. The average 1-year stock price forecast is 14.88% higher than the current stock price, while the lowest is ₹170.00 (-3.79%) and the highest is ₹255.00 (+44.31%).
Price Target: ₹203.00 (+14.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Piramal Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Jan '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 8 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 11 |
Financial Forecast
Revenue This Year
100.90B
from 88.69B
Increased by 13.76%
Revenue Next Year
115.49B
from 100.90B
Increased by 14.46%
EPS This Year
1.37
from -0.98
EPS Next Year
4.21
from 1.37
Increased by 206.63%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 102.8B | ||
| Avg | 100.9B | ||
| Low | 96.4B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 15.9% | ||
| Avg | 13.8% | ||
| Low | 8.7% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 2.30 | ||
| Avg | 1.37 | ||
| Low | 0.80 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |